Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by BeiGene, Ltd.

< Previous 1 2 3 Next >
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene to Present at Upcoming Investor Conferences
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene to Present at the Jefferies London Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback